Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DXCM DexCom	$72.10 +0.3%	$63.58	$54.11 ▼ $89.98	$27.82B	1.4	7.01 million shs	6.73 million shs
HCA HCA Healthcare	$394.40 +0.5%	$465.16	$330.00 ▼ $556.52	$87.42B	1.18	1.56 million shs	1.11 million shs
LLY Eli Lilly and Company	$1,066.59 +2.4%	$942.87	$623.78 ▼ $1,133.95	$1.00T	0.48	3.50 million shs	3.47 million shs
NVO Novo Nordisk A/S	$44.91 +1.2%	$40.29	$35.12 ▼ $81.44	$200.75B	0.77	17.38 million shs	10.77 million shs
PODD Insulet	$154.87 -1.3%	$191.53	$145.59 ▼ $354.88	$10.73B	1.2	1.79 million shs	949,131 shs
RMD ResMed	$208.04 -0.5%	$219.73	$198.61 ▼ $293.81	$30.31B	0.84	1.50 million shs	1.10 million shs
SPY SPDR S&P 500 ETF Trust	$745.64 +0.4%	$694.34	$575.60 ▼ $749.53	$763.60B	1	75.66 million shs	41.64 million shs
XLV Health Care Select Sector SPDR Fund	$149.89 +1.2%	$146.52	$127.96 ▼ $160.59	$39.29B	0.58	12.71 million shs	6.92 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DXCM DexCom	0.00%	+16.99%	+14.99%	-1.34%	-15.07%
HCA HCA Healthcare	0.00%	-6.69%	-16.85%	-26.00%	+3.13%
LLY Eli Lilly and Company	0.00%	+6.11%	+16.19%	+5.76%	+47.26%
NVO Novo Nordisk A/S	0.00%	+0.45%	+16.53%	-5.32%	-34.14%
PODD Insulet	0.00%	+5.03%	-19.43%	-35.98%	-52.27%
RMD ResMed	0.00%	+2.97%	-5.32%	-19.67%	-15.31%
SPY SPDR S&P 500 ETF Trust	0.00%	+0.88%	+5.25%	+8.15%	+27.93%
XLV Health Care Select Sector SPDR Fund	0.00%	+3.30%	+2.50%	-4.42%	+13.92%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DXCM DexCom	$72.10 +0.3%	$63.58	$54.11 ▼ $89.98	$27.82B	1.4	7.01 million shs	6.73 million shs
HCA HCA Healthcare	$394.40 +0.5%	$465.16	$330.00 ▼ $556.52	$87.42B	1.18	1.56 million shs	1.11 million shs
LLY Eli Lilly and Company	$1,066.59 +2.4%	$942.87	$623.78 ▼ $1,133.95	$1.00T	0.48	3.50 million shs	3.47 million shs
NVO Novo Nordisk A/S	$44.91 +1.2%	$40.29	$35.12 ▼ $81.44	$200.75B	0.77	17.38 million shs	10.77 million shs
PODD Insulet	$154.87 -1.3%	$191.53	$145.59 ▼ $354.88	$10.73B	1.2	1.79 million shs	949,131 shs
RMD ResMed	$208.04 -0.5%	$219.73	$198.61 ▼ $293.81	$30.31B	0.84	1.50 million shs	1.10 million shs
SPY SPDR S&P 500 ETF Trust	$745.64 +0.4%	$694.34	$575.60 ▼ $749.53	$763.60B	1	75.66 million shs	41.64 million shs
XLV Health Care Select Sector SPDR Fund	$149.89 +1.2%	$146.52	$127.96 ▼ $160.59	$39.29B	0.58	12.71 million shs	6.92 million shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DXCM DexCom	0.00%	+16.99%	+14.99%	-1.34%	-15.07%
HCA HCA Healthcare	0.00%	-6.69%	-16.85%	-26.00%	+3.13%
LLY Eli Lilly and Company	0.00%	+6.11%	+16.19%	+5.76%	+47.26%
NVO Novo Nordisk A/S	0.00%	+0.45%	+16.53%	-5.32%	-34.14%
PODD Insulet	0.00%	+5.03%	-19.43%	-35.98%	-52.27%
RMD ResMed	0.00%	+2.97%	-5.32%	-19.67%	-15.31%
SPY SPDR S&P 500 ETF Trust	0.00%	+0.88%	+5.25%	+8.15%	+27.93%
XLV Health Care Select Sector SPDR Fund	0.00%	+3.30%	+2.50%	-4.42%	+13.92%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DXCM DexCom	2.92	Moderate Buy	$82.21	14.02% Upside
HCA HCA Healthcare	2.63	Moderate Buy	$515.77	30.78% Upside
LLY Eli Lilly and Company	2.87	Moderate Buy	$1,220.37	14.42% Upside
NVO Novo Nordisk A/S	2.13	Hold	$65.56	45.99% Upside
PODD Insulet	2.74	Moderate Buy	$254.96	64.63% Upside
RMD ResMed	2.73	Moderate Buy	$286.18	37.56% Upside
SPY SPDR S&P 500 ETF Trust	2.82	Moderate Buy	$745.64	N/A
XLV Health Care Select Sector SPDR Fund	2.76	Moderate Buy	$149.89	N/A

Current Analyst Ratings Breakdown

Latest HCA, DXCM, LLY, XLV, PODD, NVO, RMD, and SPY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/22/2026	RMD ResMed	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C+) ➝ Hold (C)
5/22/2026	LLY Eli Lilly and Company	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$1,283.00
5/21/2026	LLY Eli Lilly and Company	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$1,350.00
5/21/2026	LLY Eli Lilly and Company	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
5/21/2026	LLY Eli Lilly and Company	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target		$1,300.00 ➝ $1,330.00
5/20/2026	PODD Insulet	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform
5/19/2026	LLY Eli Lilly and Company	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B) ➝ Buy (B-)
5/19/2026	HCA HCA Healthcare	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Neutral	$535.00 ➝ $490.00
5/18/2026	HCA HCA Healthcare	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B) ➝ Buy (B-)
5/18/2026	DXCM DexCom	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Buy	$100.00 ➝ $82.00
5/18/2026	DXCM DexCom	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Underweight	$67.00 ➝ $64.00

(Data available from 5/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DXCM DexCom	$4.66B	5.97	$2.77 per share	26.04	$7.66 per share	9.41
HCA HCA Healthcare	$75.60B	1.16	$45.28 per share	8.71	($13.42) per share	-29.39
LLY Eli Lilly and Company	$65.18B	15.41	$25.17 per share	42.37	$33.13 per share	32.19
NVO Novo Nordisk A/S	$327.80B	0.61	$4.68 per share	9.59	$7.12 per share	6.31
PODD Insulet	$2.90B	3.70	$6.32 per share	24.49	$18.81 per share	8.23
RMD ResMed	$5.15B	5.89	$11.20 per share	18.57	$44.56 per share	4.67
SPY SPDR S&P 500 ETF Trust	N/A	N/A	N/A	N/A	N/A	N/A
XLV Health Care Select Sector SPDR Fund	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DXCM DexCom	$836.30M	$2.34	30.81	23.87	1.19	19.31%	33.33%	13.19%	7/29/2026 (Estimated)
HCA HCA Healthcare	$6.78B	$29.08	13.56	11.96	1.25	8.89%	-295.93%	11.21%	7/24/2026 (Estimated)
LLY Eli Lilly and Company	$20.64B	$28.15	37.89	24.11	1.16	34.98%	105.77%	23.76%	8/5/2026 (Estimated)
NVO Novo Nordisk A/S	$15.51B	$4.26	10.54	13.05	4.01	37.23%	63.31%	22.19%	8/5/2026 (Estimated)
PODD Insulet	$247.10M	$4.30	36.02	19.36	1.22	10.44%	26.87%	12.01%	8/6/2026 (Estimated)
RMD ResMed	$1.40B	$10.37	20.06	17.18	1.33	27.44%	25.35%	18.69%	7/30/2026 (Estimated)
SPY SPDR S&P 500 ETF Trust	N/A	N/A	25.94	N/A	N/A	N/A	N/A	N/A	N/A
XLV Health Care Select Sector SPDR Fund	N/A	N/A	21.15	N/A	N/A	N/A	N/A	N/A	N/A

Latest HCA, DXCM, LLY, XLV, PODD, NVO, RMD, and SPY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/6/2026	Q1 2026	NVO Novo Nordisk A/S	$0.87	$1.04	+$0.17	$1.69	$10.86 billion	$10.85 billion
5/6/2026	Q1 2026	PODD Insulet	$1.19	$1.42	+$0.23	$1.30	$729.89 million	$761.70 million
4/30/2026	Q1 2026	DXCM DexCom	$0.47	$0.56	+$0.09	$0.51	$1.17 billion	$1.19 billion
4/30/2026	Q1 2026	LLY Eli Lilly and Company	$6.97	$8.55	+$1.58	$8.26	$17.82 billion	$19.80 billion
4/30/2026	Q3 2026	RMD ResMed	$2.79	$2.86	+$0.07	$2.74	$1.42 billion	$1.43 billion
4/24/2026	Q1 2026	HCA HCA Healthcare	$7.19	$7.15	-$0.04	$7.15	$19.09 billion	$19.11 billion
3/31/2026	Q1 2026	NVO Novo Nordisk A/S	N/A	$1.0270	N/A	$1.69	N/A	$10.85 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
DXCM DexCom	N/A	N/A	N/A	N/A	N/A
HCA HCA Healthcare	$3.12	0.79%	+30.19%	10.73%	6 Years
LLY Eli Lilly and Company	$6.92	0.65%	+15.18%	24.58%	11 Years
NVO Novo Nordisk A/S	$1.74	3.87%	+21.74%	40.85%	N/A
PODD Insulet	N/A	N/A	N/A	N/A	N/A
RMD ResMed	$2.40	1.15%	+6.33%	23.14%	13 Years
SPY SPDR S&P 500 ETF Trust	$7.38	0.99%	N/A	N/A	N/A
XLV Health Care Select Sector SPDR Fund	$2.50	1.67%	N/A	N/A	N/A

Latest HCA, DXCM, LLY, XLV, PODD, NVO, RMD, and SPY Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/24/2026	HCA HCA Healthcare	quarterly	$0.78	0.72%	6/16/2026	6/16/2026	6/30/2026
4/30/2026	RMD ResMed	quarterly	$0.60	1.18%	5/14/2026	5/14/2026	6/18/2026
5/4/2026	LLY Eli Lilly and Company	quarterly	$1.73	0.69%	5/15/2026	5/15/2026	6/10/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DXCM DexCom	0.42	1.95	1.64
HCA HCA Healthcare	N/A	0.83	0.75
LLY Eli Lilly and Company	1.26	1.50	1.10
NVO Novo Nordisk A/S	0.59	0.79	0.56
PODD Insulet	0.71	2.49	1.81
RMD ResMed	0.06	3.01	2.33
SPY SPDR S&P 500 ETF Trust	N/A	N/A	N/A
XLV Health Care Select Sector SPDR Fund	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DXCM DexCom	97.75%
HCA HCA Healthcare	62.73%
LLY Eli Lilly and Company	82.53%
NVO Novo Nordisk A/S	11.54%
PODD Insulet	N/A
RMD ResMed	54.98%
SPY SPDR S&P 500 ETF Trust	63.54%
XLV Health Care Select Sector SPDR Fund	N/A

Insider Ownership

Company	Insider Ownership
DXCM DexCom	0.28%
HCA HCA Healthcare	1.50%
LLY Eli Lilly and Company	0.14%
NVO Novo Nordisk A/S	0.07%
PODD Insulet	0.36%
RMD ResMed	0.65%
SPY SPDR S&P 500 ETF Trust	N/A
XLV Health Care Select Sector SPDR Fund	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DXCM DexCom	11,000	385.87 million	384.79 million	Optionable
HCA HCA Healthcare	320,000	221.84 million	218.51 million	Optionable
LLY Eli Lilly and Company	50,000	941.74 million	940.42 million	Optionable
NVO Novo Nordisk A/S	69,505	4.47 billion	4.46 billion	Optionable
PODD Insulet	5,400	69.27 million	69.02 million	Optionable
RMD ResMed	10,600	145.68 million	144.73 million	Optionable
SPY SPDR S&P 500 ETF Trust	N/A	1.02 billion	N/A	Not Optionable
XLV Health Care Select Sector SPDR Fund	N/A	262.11 million	N/A	Not Optionable

HCA, DXCM, LLY, XLV, PODD, NVO, RMD, and SPY Headlines

Recent News About These Companies

Health Care Select Sector SPDR Fund (NYSEARCA:XLV) Shares Pass Below Two Hundred Day Moving Average - Here's Why

May 21 at 3:14 AM | americanbankingnews.com

State Street Health Care Select Sector SPDR ETF (XLV)

May 20, 2026 | finance.yahoo.com

When 2022 Tore Through the S&P 500, This Healthcare ETF Barely Flinched. Why Isn’t It in More Retirement Accounts?

May 20, 2026 | finance.yahoo.com

When 2022 Tore Through the S&P 500, This Healthcare ETF Barely Flinched. Why Isn't It in More Retirement Accounts?

May 20, 2026 | 247wallst.com

Ditch or Double Down on This Pharma ETF as Trump Adjusts Drug Prices?

May 19, 2026 | 247wallst.com

These Stocks Could Be the Biggest Winners of the 2026 Midterms (XLV)

...

May 18, 2026 | marketbeat.com

Why the Healthcare Sector Warrants Concentrated Exposure

May 13, 2026 | etftrends.comE

April Jobs Data Put Focus on These Sector ETFs & Stocks

May 13, 2026 | zacks.com

Weekly ETFs: Eight of 11 sectors record outflows; financial sector leads inflows

May 5, 2026 | seekingalpha.com

Healthcare earnings impress with 86% beat rate, yet sector lags: Earnings Scorecard

May 3, 2026 | seekingalpha.com

Healthcare’s Defensive Promise Crumbles: XLV Down 7% While SPY Rises 5% in 2026

April 29, 2026 | aol.comA

Healthcare's Defensive Promise Crumbles: XLV Down 7% While SPY Rises 5% in 2026

April 29, 2026 | 247wallst.com

When the Market Sold Off in 2022, This Healthcare ETF Beat the S&P 500 by 16 Percentage Points. With Volatility Back, That History Is Worth Revisiting

April 25, 2026 | 247wallst.com

Should You Invest in the State Street Health Care Select Sector SPDR ETF ETF (XLV)?

April 20, 2026 | zacks.com

What Johnson & Johnson Earnings Signal for Healthcare ETFs

April 14, 2026 | etftrends.comE

Mid-cap healthcare stocks with A grade EPS revisions ahead of earnings

April 10, 2026 | msn.com

Likely Sector ETF & Stock Winners From March Jobs Report

April 6, 2026 | zacks.com

Healthcare among laggards in Q1; MRNA and DVA lead gainers while HUM drags

April 1, 2026 | msn.com

Consumer Sentiment Weakens: ETFs That Are Worth a Look

April 1, 2026 | zacks.com

What Q1 Earnings Could Mean for the S&P 500 Uptrend (XLV)

...

March 24, 2026 | marketbeat.com

Stagflation Scare? ETFs May Help Protect Your Portfolio

March 24, 2026 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

HCA, DXCM, LLY, XLV, PODD, NVO, RMD, and SPY Company Descriptions

DexCom NASDAQ:DXCM

$72.10 +0.20 (+0.28%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$72.59 +0.49 (+0.68%)

As of 05/22/2026 07:54 PM Eastern

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

HCA Healthcare NYSE:HCA

$394.40 +1.84 (+0.47%)

Closing price 05/22/2026 03:59 PM Eastern

Extended Trading

$395.84 +1.44 (+0.36%)

As of 05/22/2026 07:19 PM Eastern

HCA Healthcare, Inc., through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy. The company also operates outpatient health care facilities consisting of freestanding ambulatory surgery centers, freestanding emergency care facilities, urgent care facilities, walk-in clinics, diagnostic and imaging centers, rehabilitation and physical therapy centers, radiation and oncology therapy centers, physician practices, and various other facilities. In addition, it operates behavioral hospitals, which provide therapeutic programs comprising child, adolescent and adult psychiatric care, adolescent and adult alcohol, drug abuse treatment, and counseling services. The company was formerly known as HCA Holdings, Inc. HCA Healthcare, Inc. was founded in 1968 and is headquartered in Nashville, Tennessee.

Eli Lilly and Company NYSE:LLY

$1,066.59 +24.94 (+2.39%)

Closing price 05/22/2026 03:59 PM Eastern

Extended Trading

$1,065.00 -1.59 (-0.15%)

As of 05/22/2026 08:00 PM Eastern

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Novo Nordisk A/S NYSE:NVO

$44.91 +0.52 (+1.17%)

Closing price 05/22/2026 03:59 PM Eastern

Extended Trading

$44.90 -0.01 (-0.03%)

As of 05/22/2026 07:59 PM Eastern

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Insulet NASDAQ:PODD

$154.87 -2.02 (-1.29%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$154.70 -0.18 (-0.11%)

As of 05/22/2026 07:59 PM Eastern

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

ResMed NYSE:RMD

$208.04 -0.95 (-0.45%)

Closing price 05/22/2026 03:59 PM Eastern

Extended Trading

$208.05 +0.02 (+0.01%)

As of 05/22/2026 07:59 PM Eastern

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN's software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.

SPDR S&P 500 ETF Trust NYSEARCA:SPY

$745.64 +2.92 (+0.39%)

Closing price 05/22/2026 04:10 PM Eastern

Extended Trading

$743.96 -1.68 (-0.23%)

As of 05/22/2026 08:00 PM Eastern

SPDR S&P 500 ETF Trust (the Trust) is a unit investment trust. The Trust seeks to provide investment results that, before expenses, correspond generally to the price and yield performance of the S&P 500 Index (the Index). The Trust seeks to achieve this investment objective by holding a portfolio of the common stocks that are included in the Index (the Portfolio), with the weight of each stock in the Portfolio substantially corresponding to the weight of such stock in the Index. The Trust invests in a range of sectors, including pharmaceuticals; oil, gas and consumable fuels; technology hardware storage and peripherals; insurance; information technology (IT) services; healthcare providers and services; semiconductors and semiconductor equipment; hotels, restaurants and leisure, communications equipment; commercial services and supplies; road and rail; real estate management and development; containers and packaging; professional services, and paper and forest products.

Health Care Select Sector SPDR Fund NYSEARCA:XLV

$149.89 +1.74 (+1.17%)

Closing price 05/22/2026 04:10 PM Eastern

Extended Trading

$149.60 -0.28 (-0.19%)

As of 05/22/2026 07:53 PM Eastern

Health Care Select Sector SPDR Fund (the Fund) seeks to closely match the returns and characteristics of the S&P Health Care Select Sector Index (the Index). The companies included in the Index are selected on the basis of general industry classification from a universe of companies defined by the Standard & Poor's 500 Composite Stock Index (S&P 500). The Health Care Select Sector Index includes companies from the industries, such as pharmaceuticals, healthcare providers and services, healthcare equipment and supplies, biotechnology, life sciences tools and services, and healthcare technology. Under normal market conditions, the Fund generally invests substantially all, but at least 95%, of its total assets in the securities comprising the Index. State Street Global Advisors acts as the Fund's investment manager.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest HCA, DXCM, LLY, XLV, PODD, NVO, RMD, and SPY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest HCA, DXCM, LLY, XLV, PODD, NVO, RMD, and SPY Earnings

Compare Dividends

Latest HCA, DXCM, LLY, XLV, PODD, NVO, RMD, and SPY Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

HCA, DXCM, LLY, XLV, PODD, NVO, RMD, and SPY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

HCA, DXCM, LLY, XLV, PODD, NVO, RMD, and SPY Company Descriptions

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools